PAVmed (FRA:1P5) Cyclically Adjusted FCF per Share: €-59.71 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1P5 PAVmed Inc FRA:1P5
35 GF Score
Price €4.13
GF Value €0.93
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is PAVmed Cyclically Adjusted FCF per Share?

PAVmed FRA:1P5 -2.25% 35 Cyclically Adjusted FCF per Share is €-59.71 as of Mar. 2026. GuruFocus rates FRA:1P5 with a GF Score™ of 35/100 and a GF Value™ of €0.93 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

PAVmed's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-1.445. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-59.71 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-04), PAVmed's current stock price is €4.125. PAVmed's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-59.71. PAVmed's Cyclically Adjusted Price-to-FCF of today is .


PAVmed  (FRA:1P5) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


PAVmed Cyclically Adjusted FCF per Share Related Terms


PAVmed Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for PAVmed's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PAVmed Cyclically Adjusted FCF per Share Chart

PAVmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -31.77 -90.68

PAVmed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.98 -33.80 -47.13 -90.68 -59.71

FRA:1P5 vs BDMD, NSPR, TELA: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, PAVmed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PAVmed Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PAVmed's Cyclically Adjusted Price-to-FCF falls into.


FRA:1P5
35GF Score
PAVmed Inc FRA:1P5
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PAVmed Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PAVmed's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.445/330.2130*330.2130
=-1.445

Current CPI (Mar. 2026) = 330.2130.

PAVmed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -46.276 241.018 -63.402
201609 -36.633 241.428 -50.105
201612 -38.000 241.432 -51.974
201703 -57.033 243.801 -77.248
201706 -24.433 244.955 -32.937
201709 -66.333 246.819 -88.745
201712 -43.258 246.524 -57.943
201803 -48.216 249.554 -63.800
201806 -33.884 251.989 -44.402
201809 -27.102 252.439 -35.452
201812 -44.983 251.233 -59.124
201903 -57.133 254.202 -74.217
201906 -36.852 256.143 -47.509
201909 -37.870 256.759 -48.704
201912 -49.770 256.974 -63.955
202003 -35.392 258.115 -45.278
202006 -49.700 257.797 -63.661
202009 -45.935 260.280 -58.277
202012 -46.924 260.474 -59.487
202103 -47.140 264.877 -58.768
202106 -30.607 271.696 -37.199
202109 -37.000 274.310 -44.540
202112 -101.771 278.802 -120.538
202203 -60.708 287.504 -69.726
202206 -112.295 296.311 -125.143
202209 -99.764 296.808 -110.992
202212 -78.077 296.797 -86.868
202303 -70.861 301.836 -77.523
202306 -50.629 305.109 -54.795
202309 -41.795 307.789 -44.840
202312 -41.408 306.746 -44.576
202403 -41.721 312.332 -44.110
202406 -35.511 314.175 -37.324
202409 -5.401 315.301 -5.656
202412 0.231 315.605 0.242
202503 -0.840 319.799 -0.867
202506 -1.705 322.561 -1.745
202509 -1.067 324.800 -1.085
202512 -1.494 324.054 -1.522
202603 -1.445 330.213 -1.445

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-59.71 mean?
PAVmed (FRA:1P5) has a Cyclically Adjusted FCF per Share of €-59.71 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on PAVmed and its competitors.
Is PAVmed's Cyclically Adjusted FCF per Share too high?
PAVmed's current Cyclically Adjusted FCF per Share is €-59.71. Overall, PAVmed has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PAVmed's Cyclically Adjusted FCF per Share compare to BDMD and NSPR?
PAVmed's Cyclically Adjusted FCF per Share of €-59.71 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on PAVmed and its competitors. PAVmed's current Cyclically Adjusted FCF per Share is €-59.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PAVmed stock overvalued right now?
Based on GuruFocus' analysis, PAVmed (FRA:1P5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.93, compared to a current price of €4.13 — trading 343.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-59.71. PAVmed's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For PAVmed (FRA:1P5), the current Cyclically Adjusted FCF per Share is €-59.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PAVmed (FRA:1P5) Overvalued in 2026?

Based on GuruFocus' analysis, PAVmed stock appears to be overvalued. The current stock price of €4.13 is trading 343.5% above its estimated GF Value™ of €0.93. GuruFocus considers PAVmed to be Significantly Overvalued.

Key valuation signals for FRA:1P5:

  • Cyclically Adjusted FCF per Share: €-59.71
  • GF Value™: €0.93 vs. price of €4.13 (343.5% above fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the FRA:1P5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PAVmed Business Description

Other Exchanges PAVM:USA
Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
35GF Score

Get the complete analysis for FRA:1P5

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.13
Price
€0.93
GF Value